Propranolol in the treatment of problematic infantile hemangiomas / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
; (12): 1102-1105, 2011.
Article
em Zh
| WPRIM
| ID: wpr-814469
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE@#To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas.@*METHODS@#Oral propranolol was administered to 68 infants with heamngiomas diagnosed by clinical evaluation and adjuvant examination at 1.0~2.0 mg per kilogram of body weight per day, divided to 2 or 3 times. The patients revisited once a month. The changes of the tumor size, texture, and color were monitored and recorded at a regular interval.The adverse effects after medication were observed and managed accordingly.The short-term results were evaluated using a 4-grade system.@*RESULTS@#All the 68 infants were followed up for 3-13 months, except that 1 infants combined with other diseases and 4 withdrew.The overall response was Scale 1 in 8 infants, Scale II in 13, Scale III in 29, and Scale IV in 13. No serious adverse effects were seen, but none cured entirely as well.@*CONCLUSION@#Oral propranolol is safe and effective for infantile heamngioma with good short-term result. It could be used as the primary drug for problematic infantile hemangiomas at the rapid growth stage of hemangiomas.
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Propranolol
/
Neoplasias Cutâneas
/
Estudos Prospectivos
/
Tela Subcutânea
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Hemangioma
Tipo de estudo:
Observational_studies
Limite:
Female
/
Humans
/
Infant
/
Male
Idioma:
Zh
Revista:
Journal of Central South University(Medical Sciences)
Ano de publicação:
2011
Tipo de documento:
Article